TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue increasing to $4,084,839, and increased positive EBITDA of $376,500, resulting in a continued strong cash position for the Company.

The Company achieved revenue of $4,084,839 in Q2 2024, an increase of $661,054 or 19.31%, compared to the second quarter of 2023. The growth is primarily due to the rise in transaction revenue, as well as administration revenue resulting from the introduction of Software as a Service (SaaS) solutions to NexgenRx customers in late 2023, in addition to a significant sales pipeline being converted into revenue. In Q2 2024 the Company also reported an increase in both net income and EBITDA over the comparable period in the prior year. NexgenRx achieved a positive EBITDA of $376,500, an increase of $60,593 over Q2 last year. The Company's cash position continued to remain strong at $1,809,550, after cash dividend payouts of $354,609 to the common shareholders in June 2024.

Ron Loucks, President and CEO, stated "I am pleased to announce our Q2 financial results, which is a reflection of our growth sustainability. We continue to see growth in our top line revenue, in particular the recurring transaction and administration revenue. This year, we continue our new phase as a technology solution provider, promoting and expanding our fully managed SaaS solutions that empower our customers to self-manage their benefit plans effectively and efficiently. The Company is always evolving to meet the needs of clients."

About NexgenRx

NexgenRx is Canada's only independent full-service Third-Party Administrator and Technology Solutions Provider, offering proprietary full front-end, eligibility, enrolment, hour bank and mobile access capabilities, together with state-of-the-art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide Plan Sponsors, sophisticated administration and health benefit technology applications in a cost-effective SaaS (Software as a Service) Model.

NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The Company cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether the Company's strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company's proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in the Company's annual Management's Discussion and Analysis, as filed under the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. The Company undertakes no duty to update any of the forward-looking information to conform such information to actual results or to changes in the Company's expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801

Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393 x803

SOURCE: NexgenRx Inc.